DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins

The Drug Information Association (DIA) and the American Association of Pharmaceutical Scientists (AAPS) will co-sponsor Immunogenicity of Therapeutic Proteins (September 10 -12; Bethesda, MD).

Horsham, PA (Vocus) July 30, 2008 -- The Drug Information Association (DIA) and the American Association of Pharmaceutical Scientists (AAPS) will co-sponsor Immunogenicity of Therapeutic Proteins (http://www.diahome.org/DIAHOME/Education/FindEducationalOffering.aspx?productID=16578&eventType=Meeting) (September 10 -12; Bethesda, MD).

Discussion topics will include:

•    Current practices in immunogenicity evaluation

•    Role of preclinical assessment

•    Challenges of clinical immunogenicity assessment: case studies

•    Risk assessment and risk management

•    Regulatory perspectives

•    Future of immunogenicity assessment

“Industry practices in immunogenicity assessment are becoming more unified though challenges still exist in terms of technology and reduction to practice,” says Program Chair Steven J. Swanson, PhD, Executive Director, Medical Sciences, Clinical Immunology Department, Amgen, Inc. “This conference will review key aspects of assay development and validation as well as discuss challenges in implementation of these assays, data interpretation, and relevance to clinical outcomes.”

About the Drug Information Association (DIA) (http://www.diahome.org/):

DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, and Mumbai, India, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

About the American Association of Pharmaceutical Scientists (AAPS) (http://www.aapspharmaceutica.com/):

AAPS is a professional, scientific society of more than 13,500 members employed in industry, academia, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to public health. AAPS offers timely scientific programs, on-going education, information resources, opportunities for networking, and professional development.

Contact:

Joe Krasowski

215-293-5812

Joe.Krasowski @ diahome.org

###

Simillar Articles

		Adverse Drug Events Conference to Review Global Regulatory Requirements
		Professionals who are involved in all aspects of pharmaceutical safety should attend the Drug Information Association's Adverse Drug Events in Premarketing Clinical Trials and Postmarketing...
		BioSoteria to Deliver Changing Practices in Drug Safety, Signal Detection, and Risk Management, A...
		BioSoteria, Inc., a drug safety consulting and training company, will offer Changing Practices in Drug Safety, Signal Detection, and Risk Management, a Virtual Drug Safety Summit, on November 18....
		DIA Conference to Explore Global Pharmacovigilance and Risk Management Strategies and Regultory...
		The Drug Information Association (DIA) will host Safety is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies (December 10-12; Marina Square, Singapore).
		Oncology CRO Publishes Free "Patient Safety in Oncology Clinical Trials" Abstract for...
		Patient safety has always been the industry's focus during clinical trials. However, a recent spate of well-publicized patient safety issues has increased public scrutiny and the...
		DIA Conference to Present Latest Strategies in Clinical Trial Disclosure Compliance
		Experts from government, the pharmaceutical and biotech industries, and medical device companies will discuss best practices to ensure compliance with clinical trial disclosure laws and...